|Table of Contents|

Application of latissimus dorsi musculocutaneous flap to repair the partial defect of chest wall after neoadjuvant chemotherapy in the cT4 local advanced breast cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
865-869
Research Field:
Publishing date:

Info

Title:
Application of latissimus dorsi musculocutaneous flap to repair the partial defect of chest wall after neoadjuvant chemotherapy in the cT4 local advanced breast cancer patients
Author(s):
YAO Chengcai; HUANG Chuanqiang; LIU Changchun; CHEN Ming
Department of Breast Surgery,the 6th Hospital Affiliated South China University of Technology，Nanhai District People's Hospital of Foshan City,Guangdong Foshan 528225,China.
Keywords:
local advanced breast cancer; latissimus dorsi musculocutaneous flap; neoadjuvant chemotherapy; wound repair
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.05.015
Abstract:
Objective：To investigate the effect of applying of the latissimus dorsi musculocutaneous flap(LDMF) to repair of the partial defect of chest wall after neoadjuvant chemotherapy(NAC) in the cT4 local advanced breast cancer(cT4-LABC) patients.Methods:From December 2017 to August 2020,14 patients with cT4-LABC were retrospectively analyzed,who underwent local radical mastectomy of breast cancer after anti-infection and NAC achieved clinical benefit(PR+SD),LDMF was applied immediately to repair the defect of chest wall.Results:In the 14 patients,13(13/14,92.9%) completed the established cycle of NAC,and 1 case completed only 2 cycles of NAC(elimination study).In the 13 patients included in the study,there were no CR and PD case,PR 12 cases(12/13,92.31%),SD 1 case(1/13,7.69%),according to the criteria of RECIST 1.1,NAC clinical benefit rate(CBR) was 100%(13/13).All the 13 patients successfully completed the operation.The operation time was 4~6 hours.The bleeding was 200~300 mL during the operation.The skin necrosis was found in 2 cases(2/13,15.38%) after the operation and were healed by changing the dressings,and a small amount of seroma were appeared in 8 cases(8/13,61.54%) after the extubation and were disappeared by drainaging and pressuring bandage treatment.Follow-up time was 1~36 months,median follow-up was 22 months.1 case had local recurrence(1/13,7.69%).3 cases had distant metastasis(3/13,23.08%).2 cases died(2/13,15.38%).Latissimus dorsi function was good in all patients.Upper limb movement was basically normal.Conclusion:It is feasible and effective to immediately use LDMF to repair partial defect of chest wall after effective clinical treatment in cT4-LABC patients.

References:

[1] TRYFONIDIS K,SENKUS E,CARDOSO MJ,et al.Management of locally advanced breast cancer-perspectives and future directions［J］.Nat Rev Clin Oncol,2015,12(3):147-162.
[2] SIMOS D,CLEMONS M,GINSBURG OM,et al.Definition and consequences of locally advanced breast cancer［J］.Curr Opin Support Palliat Care,2014,8(1):33-38.
[3] CHIN SN,GREEN CM,GORDON-STRACHAN GM,et al.Locally advanced breast cancer in Jamaica:prevalence,disease characteristics and response to preoperative therapy［J］.Asian Pac J Cancer Prev,2014,15(7):3323-3326.
[4] 中国抗癌协会乳腺癌专业委员会.中国晚期乳腺癌规范诊疗指南（2020版）［J］.中华肿瘤杂志,2020,42(10):781-797. Breast Cancer Expert Committee of China Anti-Cancer Association.Guidelines for clincal diagnosis and treatment of advanced breast cancer in China(2020 Edition)［J］.Chin J Oncol,2020,42(10):781-797.
[5] GRADISHAR WJ,ANDERSON BO,BALASSANIAN R,et al.NCCN guidelines insights:Breast cancer,version 1.2017［J］.J Natl Compr Canc Netw,2017,15(4):433-451.
[6] 廖春丽,王聪,周欣,等.DASH简式评分表中文版应用于乳腺癌病人上肢功能障碍评价研究的信效度检验［J］.护理研究,2014,28(10):3581-3583. LIAO CL,WANG C,ZHOU X,et al.Checkout reliabity and validity of Chinese version of DASH short form scale applied in upper limb dysfunction evaluation research of breast cancer patients［J］.Chinese Nursing Research,2014,28(10):3581-3583.
[7]UNTCH M,KONECNY GE,PAEPKE S,et al.Current and future role of neoadjuvant therapy for breast cancer［J］.Breast,2014,23(5):526-537.
[8] HEIL J,KUERER HM,PFOB A,et al.Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy:current evidence and future challenges［J］.Ann Oncol,2020,31(1):61-71.
[9] BHARGAVAN RV,MIRZA A,CHERIAN K,et al.Level III dissection in locally advanced breast cancer following neoadjuvant chemotherapy:a retrospective study［J］.Ann R Coll Surg Engl,2020,102(3):214-219.
[10] ARNAOUT A,BOILEAU JF,BRACKSTONE M.Surgical considerations in locally advanced breast cancer patients receiving neoadjuvant chemotherapy［J］.Curr Opin Support Palliat Care,2014,8(1):39-45.
[11] 中国乳腺癌新辅助治疗专家组.中国乳腺癌新辅助治疗专家共识(2019年版)［J］.中国癌症杂志,2019,29(5):390-400. Chinese Expert Group on Neoadjuvant Treatment of Breast Cancer.Consensus of Chinese experts on neoadjuvant treatment of Breast Cancer(2019 Edition)［J］.China Oncology,2019,29(5):390-400.
[12] FAYANJU OM,REN Y,THOMAS SM,et al.The clinical significance of breast-only and node-only pathologic complete response(pCR) after neoadjuvant chemotherapy(NACT):A review of 20000 breast cancer patients in the national cancer data base(NCDB)［J］.Ann Surg,2018,268(4):591-601.
[13] BROGLIO KR,QUINTANA M,FOSTER M,et al.Association of pathologic complete response to neoadjuvant therapy in Her-2-positive breast cancer with long-term outcomes:A Meta-analysis［J］.JAMA Oncol,2016,2(6):751-760.
[14] HUOBER J,HOLMES E,BASELGA J,et al.Survival outcomes of the NeoALTTO study(BIG 1-06):updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with Her-2-positive primary breast cancer［J］.Eur J Cancer,2019,118:169-177.
[15] LIEDTKE C,MAZOUNI C,HESS KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer［J］.J Clin Oncol,2008,26(8):1275-1281.
[16] SHARMA P,LOPEZ-TARRUELLA S,GARCIA-SAENZ JA,et al.Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel［J］.Clin Cancer Res,2018,24(23):5820-5829.
[17] BUZDAR AU,IBRAHIM NK,FRANCIS D,et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer［J］.J Clin Oncol,2005,23(16):3676-3685.
[18] ZHAO H,ZHANG J,LU Y,et al.Neoadjuvant chemotherapy in combination with surgery in the treatment of local advanced breast cancer［J］.Pak J Med Sci,2019,35(5):1402-1407.
[19] WANG L,SONG D,SONG A,et al.Application of modified designed bilobed latissimus dorsi myocutaneous flap in chest wall reconstruction of locally advanced breast cancer patients［J］.Chinese Journal of Reparative and Reconstructive Surgey,2021,35(9):1172-1176.
[20] GROTH AK,PAZIO ALB,KUSANO LDC,et al.Thoracic wall reconstruction:Surgical planning in extended malignant resections［J］.Ann Plast Surg,2020,85(5):531-538.
[21] AZUMA R,KAJITA M,KUBO S,et al.Radiation-induced thoracic necrosis with a pulmonary cutaneous fistula repaired using a free omental flap:a case report［J］.BMC Surg,2019,19(1):14-16.
[22] GAUCHER S,BOBBIO A,MANSUET-LUPO A,et al.Late costal osteomyelitis with a cutaneous fistula after flame burns:a case report［J］.J Wound Care,2016,25(2):104,106-107.
[23] VAIRINHO A,AL HINDI A,REVOL M,et al.Reconstruction of an anterior chest wall radionecrosis defect by a contralateral latissimus dorsi flap:A case report［J］.Ann Chir Plast Esthet,2018,63(2):182-186.

Memo

Memo:
广东省佛山市高层次医学人才培养基金（编号：2018B015）
Last Update: 2023-01-31